Clinical trial NCT07003256: Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCT
Official title: An Observational Study on the Promotion of Platelet Recovery by Romiplostim During Haploidentical Hematopoietic Stem Cell Transplantation
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Thalassemia in Children
Keywords: Thalassemia
Romiplostim
HSCT
Lead sponsor: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Sponsor class: OTHER
First posted: 2025-06-04
Enrollment: 30
Sex: ALL
Minimum age (years): 2
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children aged 2 - 17 years old who were diagnosed with severe thalassemia at Haikou People's Hospital and received haploidentical hematopoietic stem cell transplantation.

Brief summary: The objective of this observational study is to explore the long-term effects of roprastine given to promote platelet implantation in hematopoietic stem cell hemicongruent transplantation in children with thalassemia. The main questions it aimed to answer is:

Is roprastine safe and effective for platelet implantation in children with thalassemia hemicongruent transplantation? Participants who have already received roprastine as part of routine medical care for hematopoietic stem cell hemicongruent transplantation in children with thalassemia will answer online survey questions about the effects of their platelet implantation within 8 weeks.

Detailed description: Allogeneic hematopoietic stem cell transplantation is an important, if not the only, means of curing many diseases of the blood system. Thrombocytopenia after transplantation seriously affects the long-term survival rate of patients. allo - The incidence of thrombocytopenia in HSCT patients is 5-20% (\< 20 x 10 \^ 9/L), increasing the risk and cost of treatment. There are currently few studies on the promotion of platelet growth in children with thalassemia. Repeated infusion of platelet suspension can lead to many adverse consequences, including blood transfusion reactions, platelet homeoimmune responses, and transfusion-associated virus infections. There is a black box warning of liver toxicity in eltropopa, and the incidence of real-world liver toxicity is 11.8%. Transplant patients are prone to diarrhea, which affects the absorption of oral platelet-raising drugs. Daily subcutaneous injection increases children's pain and poor tolerance. However, the long-acting platelet-raising drugs once after transplantation are well tolerated in children with thalassemia transplantation, and the efficacy is worth looking forward to. Up to now, there is a lack of relevant clinical data on the application of roprastine to promote platelet recovery in children with thalassemia hemiphase transplantation. Therefore, this study aimed to explore the observational study of roprastine to promote platelet implantation in children with thalassemia hemiphase transplantation, and to explore the efficacy and safety of the drug.

Eligibility criteria: Inclusion Criteria:

* After undergoing Mediterranean gene testing, reviewing the history of blood transfusions, and conducting a blood routine examination, the patient was diagnosed with severe thalassemia.
* Children aged 2 - 17 years old.
* Agree to the haploidentical transplantation, and the team has evaluated that there are no transplantation contraindications.

Exclusion Criteria:

* There is a fully matched donor, and transplantation with a half - matched donor is not agreed.
* For donors and recipients, the transaminase is more than twice the normal value.
* Donor specific antibody Greater than 5000, and after antibody treatment, it should not be lower than 3000.
* Positive for hepatitis B DNA.
* There is an active infection.
* After evaluation by the transplantation team, there are contraindications for transplantation.

Primary outcomes:
measure: Platelet recovery time
timeFrame: From enrollment to 28 days after transplantation
measure: Platelet transfusion volume
timeFrame: From enrollment to 28 days after transplantation
Secondary outcomes:
measure: Adverse drug reaction rate
timeFrame: From enrollment to 28 days after transplantation
measure: Bleeding incidence rate
timeFrame: From enrollment to 28 days after transplantation
measure: Thrombosis incidence rate
timeFrame: From enrollment to 28 days after transplantation
measure: Survival rate
timeFrame: From enrollment to 28 days after transplantation
measure: Recurrence - free survival rate
timeFrame: From enrollment to 28 days after transplantation
measure: Transplant - related mortality
timeFrame: From enrollment to 28 days after transplantation
measure: Major transplant-related complications
timeFrame: From enrollment to 28 days after transplantation
measure: Cause of death
timeFrame: From enrollment to 28 days after transplantation
Other outcomes:
Locations:
city: Haikou
country: China
facility: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
state: Hainan
Study officials:
affiliation: Department of Hematology, Haikou People's Hospital
name: Xiaoyang Yang, MD
role: PRINCIPAL_INVESTIGATOR
References: